Nuvalent Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Bluebird Bio (BLUE) and Nuvalent (NUVL)
Nuvalent (NUVL) Gets a Buy From Stifel Nicolaus
Nuvalent's Promising Clinical Progress and Financial Stability Support Strong Buy Rating
Nuvalent Analyst Ratings
Nuvalent Analyst Ratings
Leerink Partners Upgrades Nuvalent to Outperform From Market Perform, Raises Price Target to $110 From $69
Nuvalent Analyst Ratings
JP Morgan Maintains Overweight on Nuvalent, Raises Price Target to $98
Guggenheim Assumes Nuvalent at Buy, Announces Price Target of $99
BMO Capital Maintains Outperform on Nuvalent, Raises Price Target to $102
Nuvalent Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Arcutis Biotherapeutics (ARQT)
Analysts' Top Healthcare Picks: Privia Health Group (PRVA), Nuvalent (NUVL)
Baird Initiates Coverage On Nuvalent With Outperform Rating, Announces Price Target of $105
Nuvalent Analyst Ratings
Wedbush Raises Nuvalent's Price Target to $99 From $82, Maintains Outperform Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nuvalent (NUVL), NewAmsterdam Pharma Company (NAMS) and Marinus (MRNS)
Hold Rating on Nuvalent Continues: Evaluating the Potential of NVL-655 and Anticipated Market Shifts
TD Cowen Keeps Their Buy Rating on Nuvalent (NUVL)